Dasabuvir

Phase 3

AbbVie Inc. (ABBV)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Hepatitis C Infection

View Full Landscape

Drug Information

Target Indication

Chronic Hepatitis C Infection

Clinical Trial

NCT02486406

Last updated: 1/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/14/2015

Exviera

Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.

Accelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ABBV

AbbVie Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

AcalabrutinibPhase 3

Chronic Lymphocytic Leukemia

Bimatoprost (SR)Phase 3

Open-Angle Glaucoma

etanerceptPhase 3

Moderate to Severe Plaque Psoriasis

EtentamigPhase 3

Multiple Myeloma

ElagolixPhase 3

Polycystic Ovary Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts